StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report sent to investors on Tuesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Down 5.1 %
Shares of NASDAQ TTNP opened at $3.32 on Tuesday. The company has a 50-day simple moving average of $3.53 and a 200-day simple moving average of $4.67. Titan Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last released its earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Stories
- Five stocks we like better than Titan Pharmaceuticals
- What Are Dividends? Buy the Best Dividend Stocks
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- What Does the Future Hold for Eli Lilly?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
